GlaxoSmithKline and its partner ChemoCentryx have started late-stage trials of GSK’786 for Crohn’s disease. The initial study is a randomised, …
GlaxoSmithKline is to develop and commercialise a drug which hopes will be a treatment for moderate-to-severe Crohn’s disease. Californian biotech …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

